Company intelligence / Profile preview

Resistance Acquisition

Menlo Park, California, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Resistance Bio is a biotechnology company focused on overcoming treatment resistance in cancer. The company utilizes its proprietary ResCu platform, which employs advanced bioengineering and machine learning to model the evolution of drug resistance in complex tumor environments. By identifying the mechanisms that allow cancer cells to survive initial treatments, Resistance Bio aims to develop novel small molecule therapies that target these resistance pathways. Their approach seeks to transform terminal diagnoses into manageable conditions by staying ahead of tumor adaptation.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Resistance Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resistance Acquisition.

Explore the full profile